Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q16384
UPID:
SSX1_HUMAN
Alternative names:
Cancer/testis antigen 5.1; Synovial sarcoma, X breakpoint 1
Alternative UPACC:
Q16384; A3KN76; Q08AJ2; Q5JQ64
Background:
Protein SSX1, also known as Cancer/testis antigen 5.1 and Synovial sarcoma, X breakpoint 1, plays a pivotal role in transcription modulation and spermatogenesis. Its involvement in these critical biological processes underscores its significance in cellular function and development.
Therapeutic significance:
Linked to Spermatogenic failure, X-linked, 5, a disorder causing male infertility through reduced sperm motility and morphological abnormalities, SSX1's role in disease highlights its potential as a target for therapeutic intervention.